Correspondence: T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation nej.md/3TmufFT #Nephrology #Immunology

Cellular therapies are showing tremendous promise for certain cancers previously thought to be incurable. DCI's Diane Reidy-Lagunes, MD, and Chenyu Lin, MD, discuss how they work and what the future may hold. duke.is/g/2wps @DukeHealth | @DukeMedSchool

Important milestone for the field: CARsgen’s satri-cel, an autologous Claudin18.2 CAR T, has been approved in China for Claudin18.2+ HER2- advanced gastric/GEJ adenocarcinoma after ≥2 prior lines. CAR T has transformed blood cancers. Solid tumors have been the harder frontier: trafficking, persistence, antigen heterogeneity, and the tumor microenvironment. This approval does not mean the problem is solved, but it shows that engineered T cells can make it across the solid tumor line. Now the work turns to durability, safety, access, earlier lines, combinations, and whether this can extend to other Claudin18.2+ tumors. prnewswire.com/news-releases…

"Building Bridges Beyond Cancer: How Oncology Infrastructure Can Help Scale Cell and Gene Therapy Across Health Systems." The Duke Center for Cell and Gene Therapy will be launching on July 6th, 2026! @DukeCancer Read more: astct.org/Nucleus/Article/bu…

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study ashpublications.org/blood/ar…

🚨 The FDA approved oral decitabine and cedazuridine tablets with venetoclax for newly diagnosed AML in adults ≥75 years, or who have comorbidities that preclude the use of intensive induction chemotherapy. hubs.ly/Q04gprcV0 #leusm #AML #leukemia #oncology | @FDAOncology

FDA to reconsider treatment for rare cancer after its surprise rejection statnews.com/2026/05/07/fda-… via @statnews

When a phase 1 trial is published in @NEJM, you can bet it will be impactful. Here, the p53 reactivator rezatapopt showed an ORR 20% among 77 pts with TP53 mutant (Y220C) advanced tumors. Are we getting closer to drug the most undruggable of all mutations? nejm.org/doi/full/10.1056/NE…

Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning. trib.al/6nK52aA

Insightful retrospective analysis published in @BrJHaem from @ChenyuLinMD et al. from @DukeHealth suggests no clear benefit of prophylactic dexamethasone in axi-cel recipients. Following implementation at DUHS, there were no differences in the incidence, timing, duration, or severity of CRS or ICANS, nor in length of hospitalization, ICU utilization, or overall steroid exposure. These findings persisted after multivariable adjustment. Do you give prophy dex at your center? (we rarely do). doi.org/10.1111/bjh.70343Dig…

🚨 Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias. I am very pleased with this collaborative effort. Grateful to @MrinalPatnaik for his mentorship. Paper highlights 👇🏽 🧬 PPM1D mutations in clonal hematopoiesis – what really happens after chemo? Multi center study of 337 CH/CCUS patients dissects how #PPM1D and #TP53 mutations shape therapy-related clonal hematopoiesis. 👇 1️⃣ PPM1D is the signature of therapy-related CH •50% had PPM1D-mut/TP53-WT •7% had PPM1D-mut/TP53-mut •These genotypes were highly enriched in therapy-related CH/CCUS (up to 80% of cases). 2️⃣ All PPM1D mutations were truncating exon-6 variants Median VAF only 6% — small clones, but biologically meaningful. 3️⃣ Latency after genotoxic therapy was strikingly short Median time from last chemo/radiation to detection: •PPM1D-mut groups: ~6 months •TP53-mut only: ~11 months •WT/WT: ~24 months → PPM1D clones emerge fast after DNA-damaging therapy. 4️⃣ Strong link with PARP inhibitors & radioligand therapy In therapy-related CH/CCUS: •PARPi exposure: 24–26% in PPM1D-mut vs 0–3% in WT groups •Radioligand therapy: ~25–26% in PPM1D-mut vs near-zero otherwise. 5️⃣ Despite this… PPM1D clones rarely progressed Rates of transformation to MDS/CMML: •PPM1D-mut/TP53-WT: 2% •PPM1D-mut/TP53-mut: 4% •TP53-mut only: 18% •WT/WT: 12% AML transformation occurred only in WT/WT group. 6️⃣ When both PPM1D & TP53 are present, neither always “wins” Among co-mutated patients: •~⅓ #PPM1D-dominant •~⅓ #TP53-dominant •~⅓ co-dominant Therapy-related CH showed more co-dominant competing clones, suggesting chemo creates a “Darwinian battlefield”. 7️⃣ The size of the PPM1D clone matters Using ROC-derived cut-off: •PPM1D VAF ≥13% → independently predicts worse PFS & OS (HR ~2.3 for both). Multiple PPM1D mutations ≠ worse outcome — it’s the clone size, not count. 8️⃣ Clinical message #PPM1D mutations are: •Common after chemo/PARPi/radioligand therapy •Often small, fast-emerging clones •Surprisingly low risk for malignant transformation, even with TP53 — unless the VAF climbs ≥13%. Take-home: PPM1D-mut CH appears to be a therapy-selected, early-emerging, usually indolent precursor state — but rising clone size may signal real danger. doi.org/10.1182/bloodadvance…

Our traditional #COMMAND_consortium meetup at #ASH25 — always a highlight. So proud of this incredible group. @Dr_RoryShallis @Anand_88_Patel @AlexColtoff @ChenyuLinMD @CharlieFoucar #Ehab_Atallah #Eric_Winer we missed @YasminAbaza

High frequency remote digital monitoring detects CRS in #CART and #BiTE ~28 hours faster than standard care. A great honor to present this work on behalf of @DukeCancer and our collaborators at #BlueSparkTechnologies and #Takeda. #ASH25

DCI is participating in a national clinical trial that could reshape the future of CAR T-cell therapy for patients with aggressive lymphoma. duke.is/w/8xat @DukeMedSchool | @DukeHealth | @DukeHMCT

🚨 Exciting news for our leukemia patients! Ziftomenib just received FDA approval for relapsed/refractory NPM1-mutated AML — #leusm @KuraOncology Brief overview of key data: 1/ Phase II trial (KOMET‑001) treated 92 adults with relapsed/refractory NPM1-m AML using once-daily Ziftomenib (600 mg) monotherapy. 2/ PE: rate of CR/CRh 3/ Results CR/CRh rate: 22%, ORR: 33% ; among responders, 61% achieved undetectable MRD 4/ Median DOR: 4.6 months (range 2.8-7.4 m) 5/ Median OS: 6.6 months (95% CI: 3.6-8.6) 6/ Activity was consistent across subgroups including those with prior venetoclax treatment or co-mutations. 7/ Safety profile: Grade ≥3 febrile neutropenia (26 %), anemia (20 %), thrombocytopenia (20 %). Differentiation syndrome occurred in ~25 % (15 % were grade 3; no grade 4/5) doi.org/10.1200/JCO-25-01694

Presented at #LIVES2025: In the EVERDAC trial involving patients with shock, results for death at day 28 indicated that management without early arterial catheter insertion was noninferior to early catheter insertion. Full trial results: nej.md/3LmOO0D Editorial: A Less Invasive Approach to Intensive Care nej.md/49b1th5

New Episode of @ASTCT Titans of Transplant, and we’re honored to have CAR-T expert Dr. Sattva Neelapu from @MDAndersonNews We talk about past, present and future of this therapy, lots of wisdom and insight you don’t want to miss it #bmtsm #CARtcell podcasts.apple.com/us/podcas…

Encouraging real world experience (N=9) from @MayoClinic on BCMA-directed CAR T in AL #amyloidosis. ➡️ 89% CRS, 22% G3+ ➡️ 1 IEC-HS, 1 CN palsy ➡️ 75% hematologic CR, 1 VGPR ➡️ 1-yr PFS and OS of 100% ➡️ both cardiac and renal responses seen ashpublications.org/bloodadv…